{"success":true,"data":{"pressRelease":{"id":"113779","rtpr_id":"nBw2pZRzla","ticker":"SLNCF","exchange":"OTC","all_tickers":["SLNCF"],"title":"Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results","author":"Business Wire","published_at":"2026-08-10T11:15:00.080Z","article_body":"Silence Therapeutics Reports Second Quarter 2026 Financial and Business\nResults\n\nSilence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company\ndeveloping novel siRNA (short interfering RNA) therapies, today reported its\nfinancial and business results for the second quarter ended June 30, 2026.\n\nBusiness Highlights\n\nDivesiran: First-in-class siRNA silencing TMPRSS6 for polycythemia vera (PV)\nand other blood disorders\n\n\n * Presented follow-up data from the Phase 1 SANRECO trial at the European\nHematology Association (EHA) 2026 Annual Congress in June 2026 demonstrating\ndurable efficacy results and potential best-in-class profile for divesiran in\nPV. The EHA 2026 poster is \navailable here\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fs27.q4cdn.com%2F622061554%2Ffiles%2Fdoc_news%2F2026%2F06%2FEHA2026-Poster-SANRECO-May-28-final.pdf&esheet=54586367&newsitemid=20260810075814&lan=en-US&anchor=available+here&index=1&md5=88019d02617142a9d29f8cf5af350ffc)\n\n.\n\n * Completed patient dosing in the Phase 2 SANRECO double-blind,\nplacebo-controlled trial evaluating divesiran 6 mg/kg (Q6W and Q12W dosing\nintervals) in 48 phlebotomy-dependent PV patients in June 2026.\n\n * American Journal of Hematology published a preclinical study authored by\nSilence scientists exploring the potential of TMPRSS6 silencing as a\ntherapeutic approach for myelodysplastic syndrome (MDS) in June 2026. You can\nread the \npublication here\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fs27.q4cdn.com%2F622061554%2Ffiles%2Fdoc_downloads%2F2026%2FJun%2FAmerican-J-Hematol-2026-Vilcassim-Therapeutic-Silencing-of-Tmprss6-Reduces-Iron-Induced-Inflammation-and-Prolongs.pdf&esheet=54586367&newsitemid=20260810075814&lan=en-US&anchor=publication+here&index=2&md5=bc91a83d36b8f76f253b5c0fdb93affa)\n\n.\n\nSLN312 (AZD1705): Phase 1 siRNA silencing ANGPTL3 with a competitive profile\nfor dyslipidemia\n\n\n * Phase 1 results generated under the Company’s AstraZeneca collaboration were\npresented by AstraZeneca during a late-breaking oral presentation at the\nEuropean Atherosclerosis Society (EAS) Congress in May. Results demonstrated a\nfavorable safety profile and dose-dependent, durable reductions in ANGPTL3\nprotein levels as well as in atherogenic lipoproteins including LDL-C, Apo-B\nand non-HDL-C. The EAS 2026 presentation is \navailable here\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fs27.q4cdn.com%2F622061554%2Ffiles%2Fdoc_news%2F2026%2F07%2FEAS-2026-Liver-Targeted-ANGPTL3-Silencing-with-AZD1705-Lowers-Atherogenic-Lipoproteins-Preclinical-Validation-and-Phase-1-Results.pdf&esheet=54586367&newsitemid=20260810075814&lan=en-US&anchor=available+here&index=3&md5=39694612a69909c47ed7cd8ea13bea22)\n\n.\n\nPre-clinical pipeline updates:\n\n\n * Generated additional preclinical data demonstrating the effect of SLN365\n(GPR146) on lipids was reproduced and not altered by co-treatment with statin\nor ezetimibe. The program is well positioned for a potential IND filing in\n2027.\n\n * Generated additional preclinical data for SLN098 (INHBE) in a diet induced\nobesity mouse model demonstrating reduced visceral fat and preservation of\nlean body mass. The program is well positioned for a potential IND filing in\n2027.\n\nSecond Quarter 2026 Financial Results\n\n\n * Cash Position: Cash and cash equivalents were $72.1 million as of June 30,\n2026.\n\n * R&D Expenses: Research and development (R&D) expenses were $9.1\nmillion for the three months ended June 30, 2026, compared to $17.6 million\nfor the three months ended June 30, 2025. The $8.4 million decrease is mainly\ndue to the zerlasiran Phase 3 readiness being completed in 2025 as well as\nreduced personnel costs.\n\n * G&A Expenses: General and administrative (G&A) expenses were $4.7\nmillion for the three months ended June 30, 2026, compared to $5.1 million for\nthe three months ended June 30, 2025.\n\n * Net Loss: Net loss was $12.3 million, or $0.09 basic and diluted net loss per\nshare for the three months ended June 30, 2026, compared to a net loss of\n$27.4 million, or $0.19 basic and diluted net loss per share for the three\nmonths ended June 30, 2025.\n\n * Total outstanding shares were 141,739,180 ordinary shares (including shares in\nthe form of American Depositary Shares) as of June 30, 2026.\n\nAbout Silence Therapeutics\n\nSilence Therapeutics is a global clinical-stage biotechnology company\ncommitted to transforming people’s lives by silencing diseases through\nprecision engineered medicines created with proprietary siRNA (short\ninterfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to\ncreate innovative siRNA therapies designed to precisely target and silence\ngenes that cause disease. The Company is advancing a growing pipeline of siRNA\nproduct candidates targeting areas of high unmet need across rare and common\ndiseases where treatments are limited or inadequate. For more information,\nplease visit https://www.silence-therapeutics.com/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.silence-therapeutics.com%2F&esheet=54586367&newsitemid=20260810075814&lan=en-US&anchor=https%3A%2F%2Fwww.silence-therapeutics.com%2F&index=4&md5=603ef4d854eb20168f47e83e76e480d3)\n.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. In some cases, you can identify\nforward-looking statements by terminology such as “aim,” “anticipate,”\n“assume,” “believe,” “contemplate,” “continue,” “could,”\n“design,” “due,” “estimate,” “expect,” “goal,”\n“intend,” “may,” “objective,” “plan,” “positioned,”\n“potential,” “predict,” “seek,” “should,” “target,”\n“will,” “would” and other similar expressions that are predictions of\nor indicate future events and future trends, or the negative of these terms or\nother comparable terminology. All statements other than statements of\nhistorical facts contained in this press release are forward-looking\nstatements. These forward-looking statements include, but are not limited to,\nstatements about: the Company’s business strategy and plans, including the\nCompany’s clinical development activities and timelines; the potential\ntherapeutic benefits of the Company’s product candidates; and the\nanticipated timing of initial topline and future results from the SANRECO\nPhase 2 trial. Forward-looking statements are not guarantees of future\nperformance and are subject to risks and uncertainties that could cause actual\nresults and events to differ materially from those anticipated, including, but\nnot limited to, risks and uncertainties related to: the company’s history of\nnet operating losses; the company’s ability to obtain necessary capital to\nfund its clinical programs; the early stages of clinical development of the\ncompany’s product candidates; the Company’s ability to obtain regulatory\napproval of and successfully commercialize its product candidates either on\nits own or with potential partners; any undesirable side effects or other\nproperties of the company’s product candidates; the Company’s reliance on\nthird-party suppliers and manufacturers; the outcomes of any future\ncollaboration agreements; and the Company’s ability to adequately maintain\nintellectual property rights for its product candidates. These and other risks\nare described in greater detail under the section titled “Risk Factors”\ncontained in the Company’s Annual Report on Form 10-K and Quarterly Reports\non Form 10-Q and the Company’s other filings with the SEC. Any\nforward-looking statements that the Company makes in this press release are\nmade pursuant to the Private Securities Litigation Reform Act of 1995, as\namended, and speak only as of the date of this press release. Except as\nrequired by law, the Company undertakes no obligation to publicly update any\nforward-looking statements, whether as a result of new information, future\nevents or otherwise.\n Silence Therapeutics plc                                                                                                                                                                     \n \n                                                                                                                                                                                            \n \nCondensed Consolidated Statements of Operations                                                                                                                                             \n \n                                                                                                                                                                                            \n \n(Unaudited, in thousands, except share and per share data)                                                                                                                                  \n                                                                                                                                                                                              \n                                                                      Three months ended June 30,                                   Six months ended June 30,                                 \n                                                                      2026                              2025                        2026                              2025                    \n Revenue                                                              $      —                          $      224                  $      422                        $      366              \n Cost of sales                                                               —                                 (85          )              (11          )                    (139         )   \n Gross profit                                                                —                                 139                         411                               227              \n Research and development costs                                              (9,148       )                    (17,647      )              (18,270      )                    (38,460      )   \n General and administrative expenses                                         (4,717       )                    (5,131       )              (11,743      )                    (12,815      )   \n Restructuring charges                                                       —                                 (1,324       )              —                                 (1,324       )   \n Operating loss                                                              (13,865      )                    (23,963      )              (29,602      )                    (52,372      )   \n Foreign currency gain/(loss), net                                           151                               (6,613       )              (331         )                    (10,382      )   \n Other income, net                                                           669                               861                         1,240                             1,830            \n Benefit from R&D credit                                                     778                               2,371                       1,469                             5,050            \n Loss before income tax expense                                              (12,267      )                    (27,344      )              (27,224      )                    (55,874      )   \n Income tax expense                                                          (1           )                    (10          )              (1           )                    (10          )   \n Net Loss                                                             $      (12,268      )             $      (27,354      )       $      (27,225      )             $      (55,884      )   \n Loss per share (basic and diluted)                                   $      (0.09        )             $      (0.19        )       $      (0.19        )             $      (0.39        )   \n Weighted average shares outstanding (basic and diluted)                     141,709,762                       141,696,047                 141,706,190                       141,687,438      \n\n Silence Therapeutics plc                                                                                                             \n \n                                                                                                                                    \n \nCondensed Consolidated Balance Sheets                                                                                               \n \n                                                                                                                                    \n \n(Unaudited, in thousands, except share and per share data)                                                                          \n                                                                                                                                      \n                                                                                 June 30, 2026              December 31, 2025         \n Current assets                                                                                                                       \n Cash and cash equivalents                                                       $        72,054            $          11,277         \n Short-term investments                                                                   —                            73,837         \n R&D benefit receivable                                                                   9,292                        22,007         \n Other current assets                                                                     12,935                       11,537         \n Total current assets                                                                     94,281                       118,658        \n Property, plant and equipment                                                            1,325                        1,581          \n Operating lease right-of-use assets                                                      117                          167            \n Goodwill                                                                                 10,325                       10,621         \n Other intangible assets                                                                  237                          288            \n Other long-term assets                                                                   127                          127            \n Total assets                                                                    $        106,412           $          131,442        \n                                                                                                                                      \n Current liabilities                                                                                                                  \n Contract liabilities                                                            $        —                 $          (168       )   \n Trade and other payables                                                                 (12,611   )                  (13,356    )   \n Operating lease liabilities, current                                                     (103      )                  (89        )   \n Total current liabilities                                                                (12,714   )                  (13,613    )   \n Contract liabilities                                                                     (55,218   )                  (55,454    )   \n Operating lease liabilities                                                              (9        )                  (71        )   \n Total liabilities                                                               $        (67,941   )       $          (69,138    )   \n Commitments and contingencies                                                                                                        \n                                                                                                                                      \n Shareholders’ equity                                                                                                                 \n Ordinary shares - par value £0.05 per share; 141,739,180 shares issued at                (10,292   )                  (10,290    )   \n June 30, 2026 (December 31, 2025: 141,701,848)                                                                                       \n Additional paid-in capital                                                               (621,152  )                  (617,562   )   \n Accumulated deficit                                                                      589,632                      562,572        \n Accumulated other comprehensive loss                                                     3,341                        2,976          \n Total shareholders' equity                                                               (38,471   )                  (62,304    )   \n                                                                                                                                      \n Total liabilities and shareholders' equity                                      $        (106,412  )       $          (131,442   )   \n\n\n \n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260810075814/en/\n(https://www.businesswire.com/news/home/20260810075814/en/)\n\nInquiries:\n\nSilence Therapeutics plc \n\nGem Hopkins, VP, Head of IR and Corporate Communications\n\nTel: +1 (646) 637-3208\n\nir@silence-therapeutics.com (mailto:ir@silence-therapeutics.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw2pZRzla","title":"Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results","author":"Business Wire","ticker":"SLNCF","created":"2026-08-10T11:15:00.080Z","tickers":["SLNCF"],"exchange":"OTC","article_body":"Silence Therapeutics Reports Second Quarter 2026 Financial and Business\nResults\n\nSilence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company\ndeveloping novel siRNA (short interfering RNA) therapies, today reported its\nfinancial and business results for the second quarter ended June 30, 2026.\n\nBusiness Highlights\n\nDivesiran: First-in-class siRNA silencing TMPRSS6 for polycythemia vera (PV)\nand other blood disorders\n\n\n * Presented follow-up data from the Phase 1 SANRECO trial at the European\nHematology Association (EHA) 2026 Annual Congress in June 2026 demonstrating\ndurable efficacy results and potential best-in-class profile for divesiran in\nPV. The EHA 2026 poster is \navailable here\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fs27.q4cdn.com%2F622061554%2Ffiles%2Fdoc_news%2F2026%2F06%2FEHA2026-Poster-SANRECO-May-28-final.pdf&esheet=54586367&newsitemid=20260810075814&lan=en-US&anchor=available+here&index=1&md5=88019d02617142a9d29f8cf5af350ffc)\n\n.\n\n * Completed patient dosing in the Phase 2 SANRECO double-blind,\nplacebo-controlled trial evaluating divesiran 6 mg/kg (Q6W and Q12W dosing\nintervals) in 48 phlebotomy-dependent PV patients in June 2026.\n\n * American Journal of Hematology published a preclinical study authored by\nSilence scientists exploring the potential of TMPRSS6 silencing as a\ntherapeutic approach for myelodysplastic syndrome (MDS) in June 2026. You can\nread the \npublication here\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fs27.q4cdn.com%2F622061554%2Ffiles%2Fdoc_downloads%2F2026%2FJun%2FAmerican-J-Hematol-2026-Vilcassim-Therapeutic-Silencing-of-Tmprss6-Reduces-Iron-Induced-Inflammation-and-Prolongs.pdf&esheet=54586367&newsitemid=20260810075814&lan=en-US&anchor=publication+here&index=2&md5=bc91a83d36b8f76f253b5c0fdb93affa)\n\n.\n\nSLN312 (AZD1705): Phase 1 siRNA silencing ANGPTL3 with a competitive profile\nfor dyslipidemia\n\n\n * Phase 1 results generated under the Company’s AstraZeneca collaboration were\npresented by AstraZeneca during a late-breaking oral presentation at the\nEuropean Atherosclerosis Society (EAS) Congress in May. Results demonstrated a\nfavorable safety profile and dose-dependent, durable reductions in ANGPTL3\nprotein levels as well as in atherogenic lipoproteins including LDL-C, Apo-B\nand non-HDL-C. The EAS 2026 presentation is \navailable here\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fs27.q4cdn.com%2F622061554%2Ffiles%2Fdoc_news%2F2026%2F07%2FEAS-2026-Liver-Targeted-ANGPTL3-Silencing-with-AZD1705-Lowers-Atherogenic-Lipoproteins-Preclinical-Validation-and-Phase-1-Results.pdf&esheet=54586367&newsitemid=20260810075814&lan=en-US&anchor=available+here&index=3&md5=39694612a69909c47ed7cd8ea13bea22)\n\n.\n\nPre-clinical pipeline updates:\n\n\n * Generated additional preclinical data demonstrating the effect of SLN365\n(GPR146) on lipids was reproduced and not altered by co-treatment with statin\nor ezetimibe. The program is well positioned for a potential IND filing in\n2027.\n\n * Generated additional preclinical data for SLN098 (INHBE) in a diet induced\nobesity mouse model demonstrating reduced visceral fat and preservation of\nlean body mass. The program is well positioned for a potential IND filing in\n2027.\n\nSecond Quarter 2026 Financial Results\n\n\n * Cash Position: Cash and cash equivalents were $72.1 million as of June 30,\n2026.\n\n * R&D Expenses: Research and development (R&D) expenses were $9.1\nmillion for the three months ended June 30, 2026, compared to $17.6 million\nfor the three months ended June 30, 2025. The $8.4 million decrease is mainly\ndue to the zerlasiran Phase 3 readiness being completed in 2025 as well as\nreduced personnel costs.\n\n * G&A Expenses: General and administrative (G&A) expenses were $4.7\nmillion for the three months ended June 30, 2026, compared to $5.1 million for\nthe three months ended June 30, 2025.\n\n * Net Loss: Net loss was $12.3 million, or $0.09 basic and diluted net loss per\nshare for the three months ended June 30, 2026, compared to a net loss of\n$27.4 million, or $0.19 basic and diluted net loss per share for the three\nmonths ended June 30, 2025.\n\n * Total outstanding shares were 141,739,180 ordinary shares (including shares in\nthe form of American Depositary Shares) as of June 30, 2026.\n\nAbout Silence Therapeutics\n\nSilence Therapeutics is a global clinical-stage biotechnology company\ncommitted to transforming people’s lives by silencing diseases through\nprecision engineered medicines created with proprietary siRNA (short\ninterfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to\ncreate innovative siRNA therapies designed to precisely target and silence\ngenes that cause disease. The Company is advancing a growing pipeline of siRNA\nproduct candidates targeting areas of high unmet need across rare and common\ndiseases where treatments are limited or inadequate. For more information,\nplease visit https://www.silence-therapeutics.com/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.silence-therapeutics.com%2F&esheet=54586367&newsitemid=20260810075814&lan=en-US&anchor=https%3A%2F%2Fwww.silence-therapeutics.com%2F&index=4&md5=603ef4d854eb20168f47e83e76e480d3)\n.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. In some cases, you can identify\nforward-looking statements by terminology such as “aim,” “anticipate,”\n“assume,” “believe,” “contemplate,” “continue,” “could,”\n“design,” “due,” “estimate,” “expect,” “goal,”\n“intend,” “may,” “objective,” “plan,” “positioned,”\n“potential,” “predict,” “seek,” “should,” “target,”\n“will,” “would” and other similar expressions that are predictions of\nor indicate future events and future trends, or the negative of these terms or\nother comparable terminology. All statements other than statements of\nhistorical facts contained in this press release are forward-looking\nstatements. These forward-looking statements include, but are not limited to,\nstatements about: the Company’s business strategy and plans, including the\nCompany’s clinical development activities and timelines; the potential\ntherapeutic benefits of the Company’s product candidates; and the\nanticipated timing of initial topline and future results from the SANRECO\nPhase 2 trial. Forward-looking statements are not guarantees of future\nperformance and are subject to risks and uncertainties that could cause actual\nresults and events to differ materially from those anticipated, including, but\nnot limited to, risks and uncertainties related to: the company’s history of\nnet operating losses; the company’s ability to obtain necessary capital to\nfund its clinical programs; the early stages of clinical development of the\ncompany’s product candidates; the Company’s ability to obtain regulatory\napproval of and successfully commercialize its product candidates either on\nits own or with potential partners; any undesirable side effects or other\nproperties of the company’s product candidates; the Company’s reliance on\nthird-party suppliers and manufacturers; the outcomes of any future\ncollaboration agreements; and the Company’s ability to adequately maintain\nintellectual property rights for its product candidates. These and other risks\nare described in greater detail under the section titled “Risk Factors”\ncontained in the Company’s Annual Report on Form 10-K and Quarterly Reports\non Form 10-Q and the Company’s other filings with the SEC. Any\nforward-looking statements that the Company makes in this press release are\nmade pursuant to the Private Securities Litigation Reform Act of 1995, as\namended, and speak only as of the date of this press release. Except as\nrequired by law, the Company undertakes no obligation to publicly update any\nforward-looking statements, whether as a result of new information, future\nevents or otherwise.\n Silence Therapeutics plc                                                                                                                                                                     \n \n                                                                                                                                                                                            \n \nCondensed Consolidated Statements of Operations                                                                                                                                             \n \n                                                                                                                                                                                            \n \n(Unaudited, in thousands, except share and per share data)                                                                                                                                  \n                                                                                                                                                                                              \n                                                                      Three months ended June 30,                                   Six months ended June 30,                                 \n                                                                      2026                              2025                        2026                              2025                    \n Revenue                                                              $      —                          $      224                  $      422                        $      366              \n Cost of sales                                                               —                                 (85          )              (11          )                    (139         )   \n Gross profit                                                                —                                 139                         411                               227              \n Research and development costs                                              (9,148       )                    (17,647      )              (18,270      )                    (38,460      )   \n General and administrative expenses                                         (4,717       )                    (5,131       )              (11,743      )                    (12,815      )   \n Restructuring charges                                                       —                                 (1,324       )              —                                 (1,324       )   \n Operating loss                                                              (13,865      )                    (23,963      )              (29,602      )                    (52,372      )   \n Foreign currency gain/(loss), net                                           151                               (6,613       )              (331         )                    (10,382      )   \n Other income, net                                                           669                               861                         1,240                             1,830            \n Benefit from R&D credit                                                     778                               2,371                       1,469                             5,050            \n Loss before income tax expense                                              (12,267      )                    (27,344      )              (27,224      )                    (55,874      )   \n Income tax expense                                                          (1           )                    (10          )              (1           )                    (10          )   \n Net Loss                                                             $      (12,268      )             $      (27,354      )       $      (27,225      )             $      (55,884      )   \n Loss per share (basic and diluted)                                   $      (0.09        )             $      (0.19        )       $      (0.19        )             $      (0.39        )   \n Weighted average shares outstanding (basic and diluted)                     141,709,762                       141,696,047                 141,706,190                       141,687,438      \n\n Silence Therapeutics plc                                                                                                             \n \n                                                                                                                                    \n \nCondensed Consolidated Balance Sheets                                                                                               \n \n                                                                                                                                    \n \n(Unaudited, in thousands, except share and per share data)                                                                          \n                                                                                                                                      \n                                                                                 June 30, 2026              December 31, 2025         \n Current assets                                                                                                                       \n Cash and cash equivalents                                                       $        72,054            $          11,277         \n Short-term investments                                                                   —                            73,837         \n R&D benefit receivable                                                                   9,292                        22,007         \n Other current assets                                                                     12,935                       11,537         \n Total current assets                                                                     94,281                       118,658        \n Property, plant and equipment                                                            1,325                        1,581          \n Operating lease right-of-use assets                                                      117                          167            \n Goodwill                                                                                 10,325                       10,621         \n Other intangible assets                                                                  237                          288            \n Other long-term assets                                                                   127                          127            \n Total assets                                                                    $        106,412           $          131,442        \n                                                                                                                                      \n Current liabilities                                                                                                                  \n Contract liabilities                                                            $        —                 $          (168       )   \n Trade and other payables                                                                 (12,611   )                  (13,356    )   \n Operating lease liabilities, current                                                     (103      )                  (89        )   \n Total current liabilities                                                                (12,714   )                  (13,613    )   \n Contract liabilities                                                                     (55,218   )                  (55,454    )   \n Operating lease liabilities                                                              (9        )                  (71        )   \n Total liabilities                                                               $        (67,941   )       $          (69,138    )   \n Commitments and contingencies                                                                                                        \n                                                                                                                                      \n Shareholders’ equity                                                                                                                 \n Ordinary shares - par value £0.05 per share; 141,739,180 shares issued at                (10,292   )                  (10,290    )   \n June 30, 2026 (December 31, 2025: 141,701,848)                                                                                       \n Additional paid-in capital                                                               (621,152  )                  (617,562   )   \n Accumulated deficit                                                                      589,632                      562,572        \n Accumulated other comprehensive loss                                                     3,341                        2,976          \n Total shareholders' equity                                                               (38,471   )                  (62,304    )   \n                                                                                                                                      \n Total liabilities and shareholders' equity                                      $        (106,412  )       $          (131,442   )   \n\n\n \n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260810075814/en/\n(https://www.businesswire.com/news/home/20260810075814/en/)\n\nInquiries:\n\nSilence Therapeutics plc \n\nGem Hopkins, VP, Head of IR and Corporate Communications\n\nTel: +1 (646) 637-3208\n\nir@silence-therapeutics.com (mailto:ir@silence-therapeutics.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-08-10T11:15:00.138507982Z","server_sent_at_ms":1786360500138},"received_at":"2026-08-10T11:15:00.289Z","source_url":"https://www.businesswire.com/news/home/20260810075814/en/"},"analysis":{"id":"102781","press_release_id":"113779","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"earnings","narrative":"Silence Therapeutics completed patient dosing in the Phase 2 SANRECO trial for its lead asset Divesiran in June 2026, marking a key operational milestone for the polycythemia vera program.\n\nFinancial results for the second quarter showed a net loss of $12.3 million, or $0.09 per share, significantly narrowed from $27.4 million in the prior-year period, with cash and cash equivalents totaling $72.1 million.\n\nThe company also reported progress on its pipeline, including positive Phase 1 data for partnered asset SLN312 (AZD1705) and preclinical updates for SLN365 and SLN098 targeting IND filings in 2027.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Phase 2 dosing complete for lead asset while burn rate cuts in half."},"keyFigures":{"revenue":0,"customDimensions":{"net_loss":12300000,"ga_expenses":4700000,"rd_expenses":9100000,"cash_position":72100000,"shares_outstanding":141739180}},"quotedText":"Completed patient dosing in the Phase 2 SANRECO double-blind, placebo-controlled trial evaluating divesiran 6 mg/kg (Q6W and Q12W dosing intervals) in 48 phlebotomy-dependent PV patients in June 2026.","namedEntities":{"people":[{"name":"Gem Hopkins","role":"VP, Head of IR and Corporate Communications"}],"products":["Divesiran","SLN312","AZD1705","SLN365","SLN098"],"companies":[{"name":"Silence Therapeutics plc","ticker":"SLN"},{"name":"AstraZeneca","relationship":"partner"}],"dollarAmounts":[{"amount":"$72.1 million","context":"cash and cash equivalents as of June 30, 2026"},{"amount":"$9.1 million","context":"Q2 2026 R&D expenses"},{"amount":"$17.6 million","context":"Q2 2025 R&D expenses"},{"amount":"$12.3 million","context":"Q2 2026 net loss"},{"amount":"$27.4 million","context":"Q2 2025 net loss"}]},"materialImpact":{"score":4,"reasoning":"Net loss narrowed significantly (>50%) year-over-year due to lower R&D expenses, extending the cash runway to $72.1 million. Operationally, the company completed patient dosing in the Phase 2 SANRECO trial for lead asset Divesiran, a key de-risking milestone."},"tickerRelevance":{"others":[],"primary":"SLNCF"},"globalImportance":25,"audienceRelevance":30,"eventTypeSecondary":["clinical_trial"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"clinical-milestone","sectorWeight":"biotech"}},"event_type":"earnings","event_type_secondary":["clinical_trial"],"sentiment":"bullish","material_impact_score":4,"narrative":"Silence Therapeutics completed patient dosing in the Phase 2 SANRECO trial for its lead asset Divesiran in June 2026, marking a key operational milestone for the polycythemia vera program.\n\nFinancial results for the second quarter showed a net loss of $12.3 million, or $0.09 per share, significantly narrowed from $27.4 million in the prior-year period, with cash and cash equivalents totaling $72.1 million.\n\nThe company also reported progress on its pipeline, including positive Phase 1 data for partnered asset SLN312 (AZD1705) and preclinical updates for SLN365 and SLN098 targeting IND filings in 2027.","key_figures":{"revenue":0,"customDimensions":{"net_loss":12300000,"ga_expenses":4700000,"rd_expenses":9100000,"cash_position":72100000,"shares_outstanding":141739180}},"named_entities":{"people":[{"name":"Gem Hopkins","role":"VP, Head of IR and Corporate Communications"}],"products":["Divesiran","SLN312","AZD1705","SLN365","SLN098"],"companies":[{"name":"Silence Therapeutics plc","ticker":"SLN"},{"name":"AstraZeneca","relationship":"partner"}],"dollarAmounts":[{"amount":"$72.1 million","context":"cash and cash equivalents as of June 30, 2026"},{"amount":"$9.1 million","context":"Q2 2026 R&D expenses"},{"amount":"$17.6 million","context":"Q2 2025 R&D expenses"},{"amount":"$12.3 million","context":"Q2 2026 net loss"},{"amount":"$27.4 million","context":"Q2 2025 net loss"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-10T13:16:21.633Z","global_importance":25,"audience_relevance":30,"importance_components":{"tickerTier":"small-cap","eventGravity":"clinical-milestone","sectorWeight":"biotech"}},"durationMs":232501,"modelName":"glm-4.7"}}